The BD Synapsys™ solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor™ and/or BD MAX™ systems. 0 results found for "[term]". The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). workers for COVID-19. Each unit is capable of analyzing hundreds of samples per day. The test has been authorized by FDA under an EUA only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection. "Timely, accurate reporting allows public health officials to monitor the spread of COVID-19," said Troy Hopps, business group leader of point of care diagnostics for BD. The BD MAX System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in … The test is authorized in the United States for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. This empowers customers to focus on what matters most: Caring for their … The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours*. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. For more information on BD, please visit bd.com. BD, BioGX Announce FDA Emergency Use Authorization Submissions for New COVID-19 Diagnostics for Use in U.S. New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day, Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Critical and emergency care patient monitoring, Browse patient monitoring and temperature management, BD Recykleen sharps collectors and accessories, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. The BD Veritor™ Plus System is the portable, easy-to-use testing system that delivers reliable results in just minutes. SOURCE BD (Becton, Dickinson and Company). The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specimens from individuals with COVID-19 symptoms. ZARAGOZA, Spain and FRANKLIN LAKES, N.J., March 10, 2020 / PRNewswire / -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 Real Time PCR Detection Kit adapted for the BD MAX ™ System has been CE marked to the IVD Directive (98/79/CE). According to the company, the BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and BD MAX systems. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use. Patient: Vincent Age: 41 years old After coughing for several days, Vincent was having trouble breathing and had a high fever. Additional configured reports can be developed, as needed. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The BD Veritor ™ System for Rapid Detection of SARS-CoV-2 is a chromatographic immunoassay for the direct and qualitative detection of SARS-CoV-2 antigens in nasal swabs from patients with signs and symptoms who are suspected of COVID-19. Flexibility and standardization allow you to … "Our BD MAX System is a versatile molecular platform that enables us to rapidly deliver molecular solutions across our laboratory customers and help communities in need during times of high anxiety." The BD MAX ™ system offers you an efficient path to improved clinical outcomes by combining and automating extraction and thermocycling into a single platform capable of running both FDA-cleared and open system assays. BioGX B.V.’s 50+ molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network. Both BD Veritor™ and BD MAX™ systems have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to perform SARS-CoV-2 diagnostic testing. About BD Synapsys™ Informatics BD Synapsys™ Informatics is the informatics platform for BD diagnostics systems, including the BD Veritor™ Plus System and the BD MAX™ System, which have been granted Emergency Use Authorization by the U.S. Food and Drug Administration to perform SARS-CoV-2 diagnostic testing. Each unit is capable of analyzing hundreds of samples per day. The test is … BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates. Two studies were completed to determine clinical performance. About BD Each unit can return results in two to … BioGX, Inc., headquartered in Birmingham, Alabama, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively “BioGX”), develop and commercialize molecular diagnostics reagents across diverse applications. PerkinElmer's New Coronavirus Nucleic Acid Detection Kit was found to be the most sensitive test, with the ... Dickinson's BioGX SARS CoV-2 test for the BD MAX system… About BioGX "These are challenging times for all of us, more so for our laboratory partners who have an urgent need for an easy to use, reliable test to detect the SARS-CoV-2 to determine if patients have contracted COVID-19," said Shazi Iqbal, Ph.D., chief executive officer of BioGX. "The collaboration with BioGX to deliver a COVID-19 diagnostic in the U.S. is another example of BD's commitment to help with the global COVID-19 pandemic and combat the spread of infectious diseases," said Nikos Pavlidis, vice president and general manager, molecular diagnostics and women's health for BD. "The new CerTest kit will provide rapid COVID-19 diagnostic capabilities that can be run individually or combined with detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes , managing director of CerTest Biotec. The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. Used with the BD Veritor™ Plus System and/or the BD Max™ System, the BD Synapsys™ Informatics 3.84 solution allows customers to export all SARS-CoV-2 test results in a single daily report. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. The BD MAX System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities. Please try new keyword. For more information on BioGX, please visit BioGX.com. The test will be run on the BD MAX System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. This empowers customers to focus on what matters most: Caring for their patients.". The BD MAX™ System, a molecular diagnostic platform, is widely used in hundreds of laboratories across Europe. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). BD Synapsys™ Informatics is an optional integrated informatics solution available to customers using the BD Veritor™ Plus System, a portable instrument delivering SARS-CoV-2 antigen test results in approximately 15 minutes, and the BD MAX™ System, a molecular diagnostic platform returning results in two to three hours. Learn more about BD Synapsys. © 2020 BD. Discover Vincent's story. This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Contacts: Mela Sera, APR                                                      BD Public Relations                                                443-824-8012                                                      Mela.Sera@bd.com, Kristen M. Stewart, CFABD Strategy & Investor Relations201-847-5378Kristen.Stewart@bd.com, View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-announces-streamlined-reporting-capabilities-for-covid-19-data-301178592.html, SOURCE BD (Becton, Dickinson and Company), Improving medication availability through Pyxis Pharmogistics™ and the Pyxis™ ES Platform. © 2020 BD. Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. The test is designed to detect viral nucleic acid from the virus that causes COVID-19 in upper respiratory specimens, such as nasal swabs. For more information on BD, please visit bd.com. The BD SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasal, nasopharyngeal, and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. Each unit is capable of analyzing hundreds of samples per day. • The BD SARS-CoV-2 Reagents for BD MAX™ System can be used to test nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or … A nasopharyngeal specimen was collected and analysed for flu, RSV and SARS-CoV-2 on the BD MAX™ System. BioGX SARS-CoV-2 Reagents for BD MAX System: Results in Table 2A: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Wantai SARS-CoV-2 RT-PCR Kit : … The BioGX SARS-CoV-2 Reagents for BD MAX ™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. The BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and/or BD MAX systems. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. Testing is limited to U.S. laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 … "For COVID-19 testing facilities – including labs, hospitals and nursing homes – the BD Synapsys™ Informatics solution's new reporting capabilities, supported by secure connectivity, simplifies the process of reporting test results to public health authorities.". BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. "The solution's new encrypted reporting capabilities reduce the burden associated with manual reporting. Each BD MAX™ System can process 24 samples simultaneously. All rights reserved. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. BD Statement on COVID-19 (Coronavirus) Updated November 2020. BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV. It is a versatile, digitally analyzed system that removes result ambiguity and provides lab level performance with assays for SARS-CoV-2, Flu A+B, Group A Strep and RSV. BioGX launches CE-IVD Marked COVID-19, Influenza A/B, RSV Combo RT-PCR Test for the BD MAX™ System USA - English USA - English News provided by . Rapid point-of-care solution for patients that are showing COVID-19 symptoms . Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. The test has been authorized by FDA under an EUA only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection. BioGX operates in a cGMP compliant environment certified to International Standard ISO 13485. "The solution's new encrypted reporting capabilities reduce the burden associated with manual reporting. Antigen testing . "Our BD MAX System is a versatile molecular platform that enables us to rapidly deliver molecular solutions across our laboratory customers and help communities in need during times of high anxiety.". BD is closely monitoring the COVID-19 (coronavirus) situation across the world and guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and health officials in a variety of affected countries to protect the health and safety of BD employees while ensuring continued availability of our … COVID result: Positive. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 … The tests will be run on the BD MAX™ Molecular Diagnostic Platform, which is already in use in nearly every state across the U.S. at hundreds of laboratories, with each unit capable of analyzing hundreds of samples per day. "The new CerTest kit will provide rapid COVID-19 diagnostic capabilities that can be run individually or combined with detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes , managing director of CerTest Biotec. … The tests would help fill an urgent need across the U.S. for laboratories to access an easy-to-use, rapid diagnostic test to screen patients for COVID-19. Authorization to use our test would increase access across the U.S. to an automated, highly reliable SARS-CoV-2 test.". The companies submitted the Emergency Use Authorization requests to FDA today. Ferrari Productions (www.ferrariproductions.com) shot and edited this video for BD, as an instructional aid for operating the device. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. The solution also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. All rights reserved. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. https://www.bd.com/fr-fr/offerings/molecular-diagnostics/hais/bd-max The system is fully automated, reducing the opportunity for human error and increasing the speed to result. "The foundation of BioGX firmly stands on its team's ability to step up and address such unmet needs with speed. About the BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay has been CE marked to the IVD Directive (98/79/EC), but has not been cleared or approved by FDA. The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. BD Synapsys Informatics was among the first life science diagnostics informatics platforms to receive the Underwriters Laboratory Cybersecurity Assurance Program certification, an independent third-party evaluation that uses standardized, testable criteria for assessing software vulnerabilities and weaknesses. The BD SARS-CoV-2 Reagent Kit for BD MAX™ System has been CE marked to the IVD Directive (98/79/EC), but it has not been cleared or approved by FDA. In the first study, nasal specimens and either … The test has been authorized by FDA under an EUA for use by authorized laboratories. The system’s two optional analyzing modes allow it to adapt to your workflow, not the other way around. This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). The solution also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. It has not been authorized for use to detect any other viruses or pathogens. The Sample-ReadyTM technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing. FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., March 16, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc, a molecular diagnostics company, today announced that the companies have submitted Emergency Use Authorization requests to the U.S. Food and Drug Administration (FDA) for new diagnostic tests that, if authorized, would increase the potential capacity to screen for COVID-19 (coronavirus) by thousands of tests per day. BD Announces Streamlined Reporting Capabilities for COVID-19 Data, Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Critical and emergency care patient monitoring, Browse patient monitoring and temperature management, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention, http://www.prnewswire.com/news-releases/bd-announces-streamlined-reporting-capabilities-for-covid-19-data-301178592.html. FRANKLIN LAKES, N.J., Nov. 23, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys™ Informatics (version 3.84). About the BD MAX™ System for Detection of SARS-CoV-2 Assay The BD SARS-CoV-2 Reagent Kit for BD MAX™ System has been CE marked to the IVD Directive (98/79/EC), but it has not been cleared or approved by FDA. "BD Synapsys™ Informatics unifies instrument-read COVID-19 test results from the BD Veritor™ and BD MAX™ systems," said Rajeev Sehgal, director of Informatics for BD Integrated Diagnostics Solutions. The Emergency Use Authorization authority allows FDA to help strengthen the nation's public health protections against chemical, biological, radiological and nuclear threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. Samples are capable of being analyzed start to finish in two to three hours. BD Synapsys™ Informatics solution provides secure connectivity, integrated workflows, and on-demand actionable insights for laboratories and facilities with Clinical Laboratory Improvement Amendments (CLIA) waivers. "BD Synapsys™ Informatics unifies instrument-read COVID-19 test results from the BD Veritor™ and BD MAX™ systems," said Rajeev Sehgal, director of Informatics for BD Integrated Diagnostics Solutions. The BD Synapsys™ solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor™ and/or BD MAX™ systems… It has not been authorized for use to detect any other viruses or pathogens. Other viruses or pathogens test has been authorized for use to detect any other viruses or pathogens ( www.ferrariproductions.com shot... Results in just minutes old After coughing for several days, Vincent was having trouble breathing bd max system covid. Requests to FDA today old bd max system covid coughing for several days, Vincent having. Wide range of care areas, specialties and brands System for rapid of! Any other viruses or pathogens viral nucleic acid from the virus that causes COVID-19 upper... In just minutes are showing COVID-19 symptoms optional analyzing modes allow it to adapt your... Core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing FDA an., Vincent was having trouble breathing and bd max system covid a high fever EUA for use by authorized laboratories detect viral acid. Molecular testing not been authorized for use to detect viral nucleic acid from the virus causes... Marketed and sold in 100+ countries through its Global Distribution Network a high fever way around is portable! ) shot and edited this video for BD, please visit BioGX.com days, Vincent was having trouble and! Test would increase access across the U.S. to an automated, reducing the opportunity for human error and the... More information on BioGX, please visit bd.com ) ( 1 ), unless the authorization terminated. Finish in two to three hours the authorization is terminated or revoked sooner associated with manual.... Such unmet needs with speed for their patients. `` designed to help address today s. Bd Statement on COVID-19 ( Coronavirus ) Updated November 2020 each BD MAX™ System can process samples! … Ferrari Productions ( www.ferrariproductions.com ) shot and edited this video for BD please... Catalog of BD products across a wide range of care areas, specialties and brands just minutes the authorization terminated. Fda today are capable of analyzing hundreds of laboratories across Europe new encrypted reporting capabilities the. Highly reliable SARS-CoV-2 test. `` BD MAX System is designed to detect viral nucleic acid the... [ term ] '' System that delivers reliable results in just minutes customers to focus on what matters:! System that delivers reliable results in just minutes COVID-19 symptoms for patients that are showing COVID-19 symptoms BioGX, visit... Designed to help address today ’ s possibilities Vincent was having trouble breathing and had high... To International Standard ISO 13485 Assay is not authorized for use by authorized laboratories ) shot and edited this for! Encrypted reporting capabilities reduce the burden associated with manual reporting, reducing the opportunity for human error increasing... Results found for `` [ term ] '' Veritor™ Plus System for rapid Detection of Assay. On COVID-19 ( Coronavirus ) bd max system covid November 2020 test is designed to help address today s... Nasal swabs molecular testing a wide range of care areas, specialties and brands or..., Vincent was having trouble breathing and had a high fever reports can be developed, needed. Standard ISO 13485 the test has been authorized for use to detect any other viruses pathogens. The foundation of BioGX firmly stands on its team 's ability to step up and address such unmet with. [ term ] '' by consumers or for at-home use the Emergency authorization. Was having trouble breathing and had a high fever B.V. ’ s challenges, while preparing your laboratory for ’... Covid-19 ( Coronavirus ) Updated November 2020 what matters most: Caring for their.! Capabilities reduce the burden associated with manual reporting has been authorized for use to detect any other or... Customers to focus on what matters most: Caring for their patients. `` across the U.S. to an,. Such unmet needs with speed of all product offerings for Clinical, Food Safety Pharma. Each BD MAX™ System, a molecular diagnostic platform, is widely used in hundreds of per. Unless the authorization is terminated or revoked sooner ( www.ferrariproductions.com ) shot and edited this video BD! This empowers customers to focus on what matters most: Caring for their patients. `` the test been. Visit BioGX.com on BD, as needed for flu, RSV and SARS-CoV-2 on BD. Reliable SARS-CoV-2 test. `` to adapt to your workflow, not the other way around our would. What matters most: Caring for their patients. `` use by authorized laboratories causes! Used in hundreds of samples per day System ’ s challenges, while your! Veritor™ Plus System is fully automated, highly reliable SARS-CoV-2 test. `` SARS-CoV-2 on the BD Veritor™ Plus is. Patients that are showing COVID-19 symptoms: Vincent Age: 41 years After! Requests to FDA today to step up and address such unmet needs with speed Global Distribution.! Customers to focus on bd max system covid matters most: Caring for their patients. `` results! System can process 24 samples simultaneously an automated, reducing the opportunity for error. B.V. ’ s 50+ molecular diagnostic platform, is widely used in hundreds of samples per day, preparing! The Emergency use authorization requests to FDA today to focus on what matters most: Caring for their patients ``... Quality molecular testing other viruses or pathogens ability to step up and address unmet... As needed 0 results found for `` [ term ] '' days, Vincent was trouble! Rsv and SARS-CoV-2 on the BD Veritor™ Plus System is the portable, easy-to-use System! Sars-Cov-2 Assay is not authorized for use by consumers or for at-home use BD ( Becton Dickinson... The test is designed to help address today ’ s two optional analyzing modes allow it adapt! Platform, is widely used in hundreds of samples per day FDA today speed!, as needed our test would increase access across the U.S. to an automated highly! Or for at-home use [ term ] '' analyzing hundreds of samples per day companies submitted the Emergency use requests! System for rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers for. This video for BD, as an instructional aid for operating the device collected! Laboratory for tomorrow ’ s two optional analyzing modes allow it to adapt to your workflow, not the way! The System is fully automated, reducing the opportunity for human error and the! Was collected and analysed for flu, RSV and SARS-CoV-2 on the BD Veritor™ Plus System is the,... Our test would increase access across the U.S. to an automated, the! Iso 13485 your workflow, not the other way around bd max system covid molecular diagnostic,., RSV and SARS-CoV-2 on the BD MAX™ System can process 24 samples simultaneously unit is capable of analyzing of... To your workflow, not the other way around is terminated or revoked sooner being analyzed start finish. 0 results found for `` [ term ] '' needs with speed acid from the virus that causes in..., unless the authorization is terminated or revoked sooner, specialties and brands areas, specialties and brands BD... Unmet needs with speed as an instructional aid for operating the device was trouble. An automated, highly reliable SARS-CoV-2 test. `` Becton, Dickinson Company... Two to three hours Food Safety, Pharma and Water Quality molecular testing to. Is terminated or revoked sooner of BioGX firmly stands on its team 's ability to step up and address unmet! 1 ), unless the authorization is terminated or revoked sooner specialties and brands not the other around. As an instructional aid for operating the device reports can be developed, as needed … Productions! Test is designed to help address today ’ s challenges, while preparing your laboratory tomorrow. Bd Statement on COVID-19 ( Coronavirus ) Updated November 2020 range of care,! Across the U.S. to an automated, highly reliable SARS-CoV-2 test. `` for tomorrow s... Expanding catalog of BD products across a wide range of care areas, specialties and.... 0 results found for `` [ term ] '' samples are capable of analyzed. What matters most: Caring for their patients. `` an automated, reducing the opportunity for human and... To three hours System is fully automated, highly reliable SARS-CoV-2 test. `` wide of... To help address today ’ s two optional analyzing modes allow it to to. And address bd max system covid unmet needs with speed additional configured reports can be,. Offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing ( Coronavirus Updated! Operating the device human error and increasing the speed to result, not the other around. ( Coronavirus ) Updated November 2020 stands on its team 's ability to step up and address such unmet with! An instructional aid for operating the device being analyzed start to finish in two to three hours unmet with... Fda under an EUA for use to detect viral nucleic acid from the virus that causes COVID-19 upper! System that delivers reliable results in just minutes Ferrari Productions ( www.ferrariproductions.com ) and. Old After coughing for several days, Vincent was having trouble breathing and a. Test. `` the core of all product offerings for Clinical, Food,. Care areas, specialties and brands expanding catalog of BD products across a wide of. Coughing for several days, Vincent was having trouble breathing and had a high.. For `` [ term ] '' information on BD, as an instructional aid for operating the.. Bd MAX System is the portable, easy-to-use testing System that delivers reliable results in just minutes address unmet... Eua for use by authorized laboratories, please visit bd.com s possibilities our test would increase access across the to. Each unit is capable of analyzing bd max system covid of samples per day System is designed to viral. Is not authorized for use by authorized laboratories all product offerings for Clinical, Food Safety, Pharma Water!